Sutezolid Dose-finding and Combination Evaluation (SUDOCU)

Study Director
Michael Hoelscher
Start Date
5 / 2021
Trial Phase
Phase II
Trial Status
all patients enrolled
Current Enrollment
Target Enrollment

75 participants have been randomized to one of five arms (15 participants per arm) to receive study medication containing bedaquiline, delamanid, and moxifloxacin with different doses of sutezolid, ranging from 0mg sutezolid up to 800mg sutezolid twice a day. Participants are randomised and stratified by site and HIV status.

Participants visit the study clinic on a weekly basis for sputum collection, safety monitoring and receipt of study medication.

After completion of three months of experimental treatment participants in the experimental arms are handed over to government TB programmes to complete their course of anti-TB treatment.

Developer Associations
Compound Associations